Wealthcare Advisory Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.44M | Sell |
19,347
-4,992
| -21% | -$658K | 0.05% | 315 |
|
|
2026
Q1 | $3.39M | Buy |
24,339
+4,792
| +25% | +$671K | 0.07% | 256 |
|
|
2025
Q4 | $2.4M | Buy |
19,547
+1,033
| +6% | +$126K | 0.05% | 313 |
|
|
2025
Q3 | $2.06M | Sell |
18,514
-13
| -0.1% | -$1.48K | 0.04% | 337 |
|
|
2025
Q2 | $2.05M | Buy |
18,527
+352
| +2% | +$37.5K | 0.05% | 321 |
|
|
2025
Q1 | $2.04M | Sell |
18,175
-88
| -0.5% | -$9.08K | 0.05% | 280 |
|
|
2024
Q4 | $1.69M | Buy |
18,263
+2,229
| +14% | +$201K | 0.05% | 308 |
|
|
2024
Q3 | $1.34M | Buy |
16,034
+1,445
| +10% | +$110K | 0.04% | 347 |
|
|
2024
Q2 | $1M | Buy |
14,589
+913
| +7% | +$60.9K | 0.03% | 382 |
|
|
2024
Q1 | $1M | Sell |
13,676
-419
| -3% | -$32.2K | 0.03% | 363 |
|
|
2023
Q4 | $1.14M | Buy |
14,095
+477
| +4% | +$37.1K | 0.05% | 286 |
|
|
2023
Q3 | $1.02M | Sell |
13,618
-984
| -7% | -$75.7K | 0.05% | 271 |
|
|
2023
Q2 | $1.13M | Sell |
14,602
-203
| -1% | -$16.2K | 0.05% | 263 |
|
|
2023
Q1 | $1.23M | Sell |
14,805
-933
| -6% | -$77.3K | 0.05% | 260 |
|
|
2022
Q4 | $1.35M | Buy |
15,738
+3,404
| +28% | +$270K | 0.06% | 226 |
|
|
2022
Q3 | $761K | Buy |
12,334
+470
| +4% | +$29.6K | 0.04% | 274 |
|
|
2022
Q2 | $733K | Buy |
+11,864
| New | +$735K | 0.04% | 251 |
|
|
2022
Q1 | – | Sell |
-3,070
| Closed | -$223K | – | 560 |
|
|
2021
Q4 | $223K | Sell |
3,070
-5,391
| -64% | -$371K | 0.01% | 518 |
|
|
2021
Q3 | $591K | Buy |
8,461
+218
| +3% | +$15.3K | 0.04% | 288 |
|
|
2021
Q2 | $568K | Sell |
8,243
-2,024
| -20% | -$135K | 0.04% | 295 |
|
|
2021
Q1 | $664K | Buy |
10,267
+5,497
| +115% | +$354K | 0.05% | 241 |
|
|
2020
Q4 | $278K | Buy |
4,770
+727
| +18% | +$43.9K | 0.02% | 333 |
|
|
2020
Q3 | $255K | Buy |
+4,043
| New | +$280K | 0.03% | 293 |
|
|
2020
Q2 | – | Sell |
-2,205
| Closed | -$165K | – | 743 |
|
|
2020
Q1 | $165K | Sell |
2,205
-1,266
| -36% | -$87.5K | 0.02% | 292 |
|
|
2019
Q4 | $226K | Buy |
3,471
+1,282
| +59% | +$83.5K | 0.03% | 278 |
|
|
2019
Q3 | $139K | Sell |
2,189
-61
| -3% | -$3.99K | 0.02% | 325 |
|
|
2019
Q2 | $152K | Buy |
2,250
+87
| +4% | +$5.72K | 0.02% | 310 |
|
|
2019
Q1 | $141K | Buy |
2,163
+4
| +0.2% | +$266 | 0.02% | 283 |
|
|
2018
Q4 | $135K | Sell |
2,159
-63
| -3% | -$4.4K | 0.03% | 268 |
|
|
2018
Q3 | $172K | Sell |
2,222
-208
| -9% | -$15.7K | 0.03% | 245 |
|
|
2018
Q2 | $172K | Sell |
2,430
-247
| -9% | -$17.4K | 0.03% | 236 |
|
|
2018
Q1 | $202K | Sell |
2,677
-246
| -8% | -$19.6K | 0.05% | 193 |
|
|
2017
Q4 | $209K | Buy |
2,923
+1,284
| +78% | +$97.5K | 0.05% | 171 |
|
|
2017
Q3 | $133K | Buy |
+1,639
| New | +$125K | 0.04% | 184 |
|
Other funds holding GILD
LMFP
CIM
ATO
CGH
Wealthcare Advisory Partners's GILD Position: Q2 2026 in Review
Wealthcare Advisory Partners reduced its Gilead Sciences (GILD) stake by 21% in Q2 2026, selling an estimated $658K and leaving 19,347 shares worth $2.44M. The position accounts for 0.05% of the portfolio, ranked #315.
Wealthcare Advisory Partners first reported a position in GILD in Q3 2017 and has held it in 34 quarters since. The position peaked at $3.39M in Q1 2026. 678 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Wealthcare Advisory Partners held 19,347 shares of Gilead Sciences worth $2.44M as of Q2 2026.
- Wealthcare Advisory Partners sold 4,992 Gilead Sciences shares in Q2 2026, an estimated $658K.
- Gilead Sciences made up 0.05% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #315 holding.
- Wealthcare Advisory Partners first reported a position in Gilead Sciences in Q3 2017 and has held it in 34 quarters since.
- Wealthcare Advisory Partners's Gilead Sciences position peaked at $3.39M in Q1 2026.
- 678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.